Rigel Pharmaceuticals has recruited the first patients in a phase 2 study designed to assess the safety of fostamatinib for the treatment of hospitalized Covid-19 patients.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,